Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity.

J Vasc Access 2017 May 28;18(3):207-213. Epub 2017 Apr 28.

Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan - ROC.

Introduction: The efficacy of antiplatelet agents in preventing thrombosis in newly formed arteriovenous graft (AVG) in hemodialysis (HD) patients has been extensively examined. The aim of this study was to investigate the possible effect of initiation of antiplatelet medications on preventing AVG thrombosis recurrence after surgical thrombectomy for acute occlusion in HD patients. Whether post-operatively antiplatelet medications have protective effects on the patency or longevity of AVG after surgical thrombectomy in HD patients has not been investigated.

Methods: We conducted a 4-year quasi-randomized study of the unassisted patency and AVG longevity for 213 HD patients with or without initiating antiplatelet drugs after receiving surgical thrombectomy for first episode of acute AVG thrombosis.

Results: From the propensity-score-matched quasi-randomized study, initiation of antiplatelet drugs after first surgical thrombectomy in HD patients did not prevent the recurrence of surgical thrombectomy (log-rank p = 0.81), but significantly decreased the longevity of the access (log-rank p = 0.034). Multivariate Cox model demonstrated that prescription of antiplatelet drugs significantly increased the risk of graft failure (adjusted hazard ratio 2.13, p = 0.025).

Conclusions: Adjunctive prescription with antiplatelet medications in HD patients after surgical thrombectomy did not prevent recurrent thrombosis of AV access, but significantly jeopardized the longevity of AVG after surgical thrombectomy.

Download full-text PDF

Source
http://dx.doi.org/10.5301/jva.5000660DOI Listing
May 2017
5 Reads

Publication Analysis

Top Keywords

surgical thrombectomy
32
antiplatelet medications
12
antiplatelet drugs
12
initiation antiplatelet
12
prescription antiplatelet
8
longevity avg
8
thrombectomy patients
8
quasi-randomized study
8
arteriovenous graft
8
avg surgical
8
recurrence surgical
8
thrombectomy
8
surgical
8
antiplatelet
7
patients
6
avg
6
longevity
5
antiplatelet medication
4
conducted 4-year
4
cox model
4

References

(Supplied by CrossRef)

Allon M et al.
Clin J Am Soc Nephrol 2007

Feldman HI et al.
J Am Soc Nephrol 1996

Dixon BS et al.
Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009

Harter HR et al.
N Engl J Med 1979

Dember LM et al.
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008

Andrassy K et al.
Klin Wochenschr 1974

Nikam MD et al.
Nephron 2015

Yevzlin AS et al.
Semin Dial 2006

Coleman CI et al.
Int J Clin Pract 2010

Dixon BS et al.
Use of aspirin associates with longer primary patency of hemodialysis grafts. J Am Soc Nephrol 2011

Irish A et al.
BMC Nephrol 2009

Similar Publications